CA
NZ
UK
AU
IND
US
CervoMed Inc. (NASDAQ: CRVO) reported a second-quarter EPS of $-0.64, notably beating the consensus estimate of $-0.89 for the period ending June 30, 2026. This performance comes against a backdrop of significant volatility, with CervoMed shares down 63.3% year-to-date. The company's ability to exceed …
DRI Healthcare Trust reported a strong second-quarter performance, with total income climbing to $50.1 million, a 13% increase from the prior year. Cash receipts also rose, increasing 16% to $46.5 million. Adjusted EBITDA soared 40% to $42.6 million, leading to an impressiveMarginof 92%.
Erasca, Inc. has made a significant leadership change by appointing Charles S. Fuchs, M.D. As President of Research & Development, effective August 10, 2026. Dr. Fuchs, a highly regarded figure in oncology with over three decades of experience, will oversee the strategic development of …
Hims & Hers Health, Inc. (NYSE: HIMS) achieved a notable revenue of approximately $753 million for the second quarter, reflecting a 38% year-over-year increase. This performance surpasses the consensus estimate, which anticipated a much narrower loss with an EPS of $-0.10 against a $-0.01 …
The rise of GLP-1 drugs like Ozempic and Wegovy is prompting a marked shift in consumer spending habits, with Bank of America investing over $250 million in these weight-loss treatments. This change highlights a broader trend toward healthier food choices and nutrient-dense diets among …
AbbVie Inc. has raised around $9.93 billion through a debt issuance involving various senior notes to finance its acquisition of Apogee Therapeutics. The issuance includes $500 million in senior floating rate notes due in 2028, $1 billion in 4.500% senior notes due in 2028, …
Alamar Biosciences, Inc. achieved a remarkable $29.4 million in revenue for the second quarter of 2026, marking an impressive 82% increase over the $16.2 million recorded in the same period last year. This quarterly performance outstripped analyst expectations, with the company's reportedEarnings Per Shareof …
Zura Bio Ltd posted a net loss of $26.3 million for the second quarter, with cash reserves at $205.1 million ensuring funding through 2028. The robust enrollment inClinical Trialspositions the company favorably for upcoming data readouts, crucial for investor confidence.Key HighlightsEnrollment in TibuSHIELD and …
Tenax Therapeutics (NASDAQ: TENX) saw its stock surge 6.9% to $1.47 in early trading after management highlighted data from the Phase III LEVEL trial of oral levosimendan in patients with heart failure with preserved ejection fraction (HFpEF). The announcement came amid a steep 87.6% …
Upstream Bio, Inc. reported an EPS of $-0.75 for the second quarter, exceeding the consensus estimate of $-0.78. The positive variance indicates clinical advancements that may bolster investor confidence as the company approaches key trial initiations.Key HighlightsQ2Research and Developmentexpenses fell to $36.1 million from …
Please wait processing your request...